Reducing the Nonindicated Use of IV Hydralazine in the Inpatient Setting

减少住院患者中静脉注射肼屈嗪的非适应症使用

阅读:1

Abstract

BACKGROUND: Elevated blood pressure (BP) affects up to 72% of hospitalized patients. Intravenous (IV) antihypertensives are indicated for hypertensive emergencies, but they are often given for asymptomatic BP elevations, leading to hypotension, acute kidney injury, and intensive care unit transfers without improving outcomes. PROJECT RATIONALE: At UConn John Dempsey Hospital, 69% of IV hydralazine use between June 2023 and January 2024 lacked appropriate indications. PROJECT SUMMARY: A redesigned order set required prescribers to select a guideline-supported indication before ordering hydralazine. The order also displayed the last 5 BPs and included hyperlinks to American Heart Association guidelines. Education sessions for residents and nurses reinforced best practices and provided alternatives for asymptomatic BP elevations. TAKE-HOME MESSAGES: Nonindicated IV hydralazine use decreased from 69% to 25%. Order set modifications had a greater impact than education alone. Embedding decision support with targeted education offers a scalable, reproducible model for safer inpatient prescribing.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。